- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Duke spin-off firm wins FDA marketing approval
Research Triangle Park, NC-The FDA has approved marketing to begin for a new, non-invasive eye scanner developed by a company spun off from Duke University's biomedical engineering department.
Research Triangle Park, NC-The FDA has approved marketing to begin for a new, non-invasive eye scanner developed by a company spun off from Duke University's biomedical engineering department.
Bioptigen Inc.'s imaging system is designed to deliver microscale, three-dimensional images of the retina and other eye surfaces 50 times faster than other scanners. The spectral domain optical coherence tomography (SD-OCT) scanners can aid in the diagnosis of glaucoma and other diseases, according to the company.
Bioptigen also is developing other imaging systems for use inside or outside the body, as well as image-processing software. The company recently received two federal research grants for further developing SD-OCT technology and for another system to be used at the genetic level.
